Skip to content

MassBio

Massachusetts Biotechnology Council

Open search form
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
  • Resources
    • 2023 Diversity, Equity, & Inclusion Report
    • 2023 Industry Snapshot
    • 2022 Massachusetts Biopharma Funding Report
    • 2022 MA Life Sciences Workforce Analysis Report
    • Economic Development
    • Biopharma Startup Toolkit
    • Career Center
    • MassBioEd
  • Events
    • Events Calendar
    • Overview of Events
    • Get Involved
  • Membership
    • Member Directory
    • Benefits of Membership
    • Savings and Rewards
    • Member News
    • Become a Member
    • Member Rates
    • Pay Company Dues
  • Savings & Rewards
    • MassBioEdge
  • Conference Center
    • MassBioHub
  • Programs
    • Bioversity at Southline Boston
    • State of Possible 2025 Report
    • Diversity, Equity, and Inclusion
    • Policy & Advocacy
    • Partnering Opportunities
    • MassBioDrive
    • Digital Health
    • BioReady Communities
  • About Us
    • About Us
    • News & Thought Leadership
    • Sponsorship Opportunities
    • Staff
    • Board of Directors
    • FAQs
    • Contact Us
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
Open search form

Member Directory

Click to Open Main Menu

Elektrofi

Life Sciences | Drug Development
Boston, MA Website

Overview

Revolutionary Protein Formulations Elektrofi engineers high-concentration, low-viscosity protein formulations in the form of Elektroject™ particles suspended in GRAS carrier liquids. While most protein formulations become nearly unusable at concentrations greater than 200 mg/mL due to high viscosity, Elektroject™ suspensions can reach concentrations greater than 500 mg/mL without exceeding a viscosity limit. Tedious and costly IV infusions can be replaced by quick and cost-effective subcutaneous injections. Administration time for healthcare professionals and their patients will drop from hours to just seconds. High-Tech Processing and Modern Applications The formulation system effectively handles a wide range of therapeutic molecules. Elektroject™ particles demonstrate bioactivity equivalent to standard formulations and can be injected through a 27-gauge needle. Elektrofi’s technology has the capacity to process increasingly complex and delicate proteins including monoclonal antibodies, bispecifics, and fusion proteins. Transforming Delivery Across the Healthcare Ecosystem Biotech companies, healthcare professionals, and many patients stand to benefit from the introduction of Electroject™ formulation. This formulation provides companies opportunities for competitive product differentiation. Replacing IV infusions with subcutaneous injections frees up hospital beds and gives time back to healthcare professionals. Most importantly, this shift will improve patient comfort, and allow them to return to their lives.

See all Members

Massachusetts Biotechnology Council

700 Technology Square, 5th Floor
Cambridge, MA 02139
617.674.5100

  • Contact
  • Privacy Policy
  • Fulfillment Policy
  • © 2024 All Rights Reserved